Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25

Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market

Enzene appoints new site lead of biologics manufacturing

He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site

Indian doctor participates in Jordan’s first robotic radical hysterectomies

India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh

The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come

Shilpa Medicare receives USFDA approval for Bortezomib injection

Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)

FMD vaccination of pastoral sheep and goat to be extended pan India: Animal Husbandry Minister

CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance

The emergence of new infections in India is a growing concern

Zydus Lifesciences to scale up US specialties business

The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US

Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth

European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24

HealthCare Global Enterprises posts Q1 FY25 PAT higher at Rs. 12.1 Cr

Our centers are performing as expected or even better